"Guggenheim's thesis rests on a binary catalyst: Topline data from Pfizer's MEVPRO-1 Phase 3 trial of mevrometostat in second-line and later metastatic castration-resistant prostate cancer (mCRPC) is expected to read out in the second half of 2026. The risk/reward is asymmetric in the bull's favor: Guggenheim sees approximately $2 per share of potential upside on a successful readout versus roughly $1 of downside on failure."
"Oncology momentum: Pfizer's oncology segment generated $4.435 billion in Q4 2025, up 9% year-over-year, with Padcev up 15%, Lorbrena up 46%, and oncology biosimilars up 77%. A MEVPRO-1 win would extend this runway into the next decade, adding a new prostate cancer franchise to an already growing portfolio."
"The non-COVID portfolio delivered 9% operational revenue growth in Q4 2025, anchored by Vyndaqel at $1.688 billion and Eliquis at $2.020 billion. This steady cash generation supports the 6.41% dividend yield at current prices, or 43 cents per share quarterly."
Pfizer's shares have increased 6.61% year-to-date, trading near $26.84, below its 52-week high. Wall Street's average price target is $28.14, indicating a cautious outlook. Guggenheim raised its target to $36, suggesting significant upside based on the upcoming MEVPRO-1 Phase 3 trial results for mevrometostat in prostate cancer. The oncology segment showed strong growth, with Q4 2025 revenues up 9%. The non-COVID portfolio also performed well, supporting a 6.41% dividend yield. Pfizer plans 20 pivotal trial starts in 2026, enhancing its pipeline depth.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]